ELKS Activators
Chemicals classified as ELKS activators, although not directly interacting with the protein, exert their influence through the modulation of calcium signaling pathways. The complexity of their action underscores the intricate nature of cellular signaling and the nuanced role that ELKS plays within these networks. Activators of this class serve as a calcium chelators, buffering the intracellular calcium levels. This action indirectly influences any calcium-dependent processes, including neurotransmitter release, a process in which ELKS involvement is critical. In addition, activators exert their influence by inhibiting the SERCA, thereby increasing the concentration of cytoplasmic calcium. This elevation in cytoplasmic calcium has the potential to modulate ELKS activity, given the protein's role in calcium-dependent processes.
On the other hand, ELKS activators inhibit L-type voltage-gated calcium channels. By reducing the influx of calcium, these compounds potentially affect ELKS activity by modulating the availability of calcium, a key factor in neurotransmitter release. Activators modulate ryanodine receptors, which regulate the release of intracellular calcium. By influencing the release of calcium from intracellular stores, these compounds indirectly influence ELKS activity. Lastly, activators inhibit the IP3 receptor, which mediates the release of calcium from intracellular stores. This action indirectly affects ELKS activity by modifying calcium signaling.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
BAPTA/AM | 126150-97-8 | sc-202488 sc-202488A | 25 mg 100 mg | $138.00 $458.00 | 61 | |
BAPTA-AM is a cell-permeable calcium chelator. By buffering intracellular calcium levels, it indirectly affects calcium-dependent processes such as neurotransmitter release, potentially modifying ERC1 activity. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin is a non-competitive inhibitor of the sarco-/endoplasmic reticulum Ca2+ ATPase (SERCA). By increasing cytoplasmic calcium concentration, it can potentially influence ERC1, given its role in calcium-dependent neurotransmitter release. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 is a mobile ion-carrier that forms a calcium-selective channel across lipid membranes, affecting calcium signaling and potentially influencing ERC1 activity. | ||||||
Cyclopiazonic Acid | 18172-33-3 | sc-201510 sc-201510A | 10 mg 50 mg | $176.00 $624.00 | 3 | |
Cyclopiazonic Acid is a specific inhibitor of the sarco-/endoplasmic reticulum Ca2+ ATPase (SERCA), like Thapsigargin, it can increase cytoplasmic calcium concentration and potentially modify ERC1 activity. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $59.00 $173.00 | 15 | |
Nifedipine is a calcium channel blocker that specifically inhibits L-type voltage-gated calcium channels. By reducing calcium influx, it can indirectly affect ERC1 activity. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
Verapamil is another calcium channel blocker that inhibits L-type voltage-gated calcium channels. Like Nifedipine, it can potentially influence ERC1 activity by reducing calcium influx. | ||||||
Dantrolene | 7261-97-4 | sc-500165 | 25 mg | $350.00 | 7 | |
Dantrolene inhibits ryanodine receptors, which regulate intracellular calcium release. By affecting calcium signaling, it can potentially influence ERC1 activity. | ||||||
Nimodipine | 66085-59-4 | sc-201464 sc-201464A | 100 mg 1 g | $61.00 $307.00 | 2 | |
Nimodipine is a calcium channel blocker that inhibits L-type voltage-gated calcium channels, potentially influencing ERC1 activity by reducing calcium influx. | ||||||
Ryanodine | 15662-33-6 | sc-201523 sc-201523A | 1 mg 5 mg | $223.00 $799.00 | 19 | |
Ryanodine is a potent modulator of the ryanodine receptor, a calcium channel found on the endoplasmic reticulum. By modulating intracellular calcium release, it can indirectly affect ERC1 activity. | ||||||
Xestospongin C | 88903-69-9 | sc-201505 | 50 µg | $510.00 | 14 | |
Xestospongin C is an inhibitor of the IP3 receptor, which mediates calcium release from intracellular stores. By affecting calcium signaling, it can potentially influence ERC1 activity. | ||||||